Clinical trials: sponsored by UNICANCER
Small Cell Lung Carcinoma
Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
This study is an academic-lead, open-label, multicenter, randomized phase II trial for frail limited disease Small Cell Lung Cancer (LD-SCLC) patients.
- Trial name
- DURVALUNG (NCT05617963)
- Testing
- Durvalumab
- Where
- 32 sites in France
- Volunteers
- 100 people
- Sponsor
- UNICANCER
Breast Cancer
Patient's Choice in the Reduction of Their Treatment in Women Over 65 Year With Breast Cancer
Standard treatment for women with early breast cancer (HR+, HER2-, T1N0) consists of the removal of the tumor from the breast by surgery with or without chemotherapy, followed by a whole-breast radiation therapy (usually one…
- Trial name
- CARTE (NCT05058196)
- Testing
- Whole breast radiotherapy, Intra Operative Radiotherapy
- Where
- France
- Volunteers
- 104 people
- Sponsor
- UNICANCER
Biliary Tract Cancer (BTC)
Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers
The goal of this clinical trial is to etablish whether adding Mitazalimab to standard chemotherapy is more effective than standard chemotherapy alone in people with advanced bile duct cancer.
- Trial name
- CROCOBIL (NCT07437287)
- Testing
- mFOLFOX regimen, Mitazalimab
- Where
- 22 sites in France
- Volunteers
- 160 people
- Sponsor
- UNICANCER
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
Overall survival (OS) of patients with advanced (stage IIIB/IV) non-small-cell lung cancer (NSCLC) remains short after the first line of treatment with a median OS of 12.2 months in non squamous NSCLC and 9.2 months in squamous…
- Conditions
- Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4
- Trial name
- NIRVANA-LUNG (NCT03774732)
- Testing
- Radiotherapy, Pembrolizumab, Chemotherapy
- Where
- 58 sites in France, Monaco
- Volunteers
- 327 people
- Sponsor
- UNICANCER
Localized Cancer
Neo-adjuvant Immunotherapy Master Trial for Localized Cancers
Most cancer treatments are developed without knowing whether the drug's targets are actually present in a patient's tumor or whether the patient is likely to benefit from the treatment.
- Trial name
- NEOREM (NCT07262489)
- Testing
- Each therapeutic NEOREM sub-protocol will mention the description of intervention
- Where
- France
- Volunteers
- 200 people
- Sponsor
- UNICANCER
Hepatocellular Carcinoma
Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
Liver cancer is a highly lethal malignancy and has become increasingly important in western countries. The management of liver cancer is complex.
- Trial name
- ALICE (NCT06904170)
- Testing
- Durvalumab Plus Tremelimumab, HAIC (GEMOX)
- Where
- 11 sites in France
- Volunteers
- 196 people
- Sponsor
- UNICANCER
DCIS, Breast Cancer
Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast
Following breast-conserving surgery (BCS) for localized ductal carcinoma in situ (DCIS) of the breast, whole-breast irradiation (WBRT) is a standard of care, reducing the absolute rate of in-breast recurrences (IBR) by more than…
- Conditions
- DCIS, Breast Cancer, Low Risk DCIS, Breast Conserving Surgery
- Trial name
- ROMANCE (NCT03878342)
- Testing
- Radiotherapy, No Radiotherapy
- Where
- 37 sites in France
- Volunteers
- 295 people
- Sponsor
- UNICANCER
Metastatic Pancreatic Adenocarcinoma
Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
This study aims to evaluate whether the combination of gemcitabine and paclitaxel allows to improve the overall survival compared to gemcitabine alone, in patients with metastatic Pancreatic Ductal Adenocarcinoma (PDAC) after…
- Trial name
- GEMPAX (NCT03943667)
- Testing
- Gemcitabine, Paclitaxel
- Where
- 26 sites in France
- Volunteers
- 211 people
- Sponsor
- UNICANCER
Non-Small Cell Lung Cancer, Sarcoma
Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
Alterations in the HER2 gene are involved in the development of cancer. These abnormalities are found at highly variable rates (from approximately 2% to 60%) in cancers of the lung, breast, stomach, bile ducts, salivary glands…
- Conditions
- Non-Small Cell Lung Cancer, Sarcoma, Head &Amp; Neck Cancer, Colorectal Carcinoma
- Trial name
- AcSé HER2 (NCT07192068)
- Testing
- Zanidatamab
- Where
- 4 sites in France
- Volunteers
- 105 people
- Sponsor
- UNICANCER
Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
The goal of this clinical trial is to test the safety of the trifluridine/tipiracil as replacement of fluoropyrimidines based chemotherapy as first line metastatic colorectal or gastroesophageal cancer regimens in patients with…
- Conditions
- Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
- Trial name
- TRIFLUOX-DP (NCT06245356)
- Testing
- Lonsurf, Oxaliplatin, Panitumumab
- Where
- 21 sites in France
- Volunteers
- 73 people
- Sponsor
- UNICANCER
Metastatic Colorectal Cancer, BRAF V600E Mutation Positive
A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
The study will be conducted in patients with metastatic colorectal cancer (mCRC) harboring a BRAFV600E mutation, to collect clinical data and biological samples to be used for research but also to gather real-world clinical data…
- Trial name
- COBRAF (NCT05639413)
- Testing
- Collection of blood samples
- Where
- 45 sites in France
- Volunteers
- 400 people
- Sponsor
- UNICANCER
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite…
- Conditions
- Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma
- Trial name
- Pan-MSI-ACSE (NCT06333314)
- Testing
- Dostarlimab, Chemotherapy
- Where
- 22 sites in France
- Volunteers
- 120 people
- Sponsor
- UNICANCER
Advanced Breast Cancer, Advanced Gastric Cancer
Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
International study that will evaluate the association of prespecified biomarkers with resistance to Antibody-drug conjugates (ADCs), a type of targeted cancer treatment currently used in clinical practice for treating different…
- Conditions
- Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer, Advanced Non Small Cell Lung Cancer (NSCLC)
- Trial name
- OASIS (NCT07259226)
- Testing
- Biological samples collection, questionnaires to collect patient reported outcomes
- Where
- France
- Volunteers
- 400 people
- Sponsor
- UNICANCER
Metastatic Breast Cancer, Metastatic Lung Cancer
Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases
Bone metastases occur frequently during the evolution of solid tumors, either isolated or associated with visceral metastases. The incidence varies between 20 and 85% depending on the primary cancer.
- Conditions
- Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Prostate Cancer, Bone Metastases
- Trial name
- STEREO-OS (NCT03143322)
- Testing
- SBRT
- Where
- 28 sites in France
- Volunteers
- 168 people
- Sponsor
- UNICANCER
Oropharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC
This is a national multicenter, randomized, stratified, open label study, aiming to compare mandibular reconstruction (MR) with or without preoperative virtual planning (PVP), in patients with oral/oropharyngeal cancer (OOPC).
- Trial name
- CURVE (NCT04725396)
- Testing
- Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP)., Conventional Mandibular Reconstruction (MR without PVP)
- Where
- 10 sites in France
- Volunteers
- 132 people
- Sponsor
- UNICANCER
Leptomeningeal Metastasis, Leptomeningeal Disease
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
The goal of this clinical trial is to evaluate the efficacy of tucatinib and capecitabine in combination with intrathecal trastuzumab on overall survival rate at 12 months in HER2-positive metastatic breast cancer (MBC) patients…
- Conditions
- Leptomeningeal Metastasis, Leptomeningeal Disease, HER2-positive Metastatic Breast Cancer
- Trial name
- ETIC-LM (NCT05800275)
- Testing
- Tucatinib Oral Tablet, Capecitabine tablets, Trastuzumab Injection
- Where
- 11 sites in France
- Volunteers
- 30 people
- Sponsor
- UNICANCER
Bladder Cancer
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy
Patients older than ≥18 years, with muscle-invasive bladder cancer unfit for radical cystectomy because of age, comorbidities, and/or patient's refusal. This study is designed as a multicentre, single-arm phase II study.
- Trial name
- BladderSpar (NCT03697850)
- Testing
- Atezolizumab
- Where
- 12 sites in France
- Volunteers
- 79 people
- Sponsor
- UNICANCER
Esophagus Cancer, Unresectable Malignant Neoplasm
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer
This study aims to assess the efficacy of durvalumab in combination with radiochemotherapy (FOLFOX and IMRT) and then as maintenance therapy for treating patients with localised unresectable oesophageal cancer.
- Trial name
- ARION (NCT03777813)
- Testing
- Durvalumab, IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)
- Where
- 7 sites in France
- Volunteers
- 112 people
- Sponsor
- UNICANCER
Metastatic Breast Cancer
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
This study is a randomized, open-label, multicentric, phase III trial conducted in patients receiving aromatase inhibitor and palbociclib as first line therapy for estrogen receptor (ER)-positive HER2-negative metastatic breast…
- Trial name
- PADA-1 (NCT03079011)
- Testing
- Palbociclib 125mg, Aromatase Inhibitors, Fulvestrant Injectable Product
- Where
- 82 sites in France
- Volunteers
- 1,017 people
- Sponsor
- UNICANCER
Hepatocellular Carcinoma by BCLC Stage
Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
Liver cancer is the third leading cause of cancer-related deaths worldwide. The majority of primary liver cancers occur as hepatocellular carcinoma (HCC), the incidence of which is increasing in many parts of the world.
- Trial name
- HESTIA (NCT05622071)
- Testing
- Tislelizumab
- Where
- 10 sites in France
- Volunteers
- 50 people
- Sponsor
- UNICANCER